<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-0390</journal-id>
<journal-title><![CDATA[Revista Médica del Uruguay]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Méd. Urug.]]></abbrev-journal-title>
<issn>1688-0390</issn>
<publisher>
<publisher-name><![CDATA[Sindicato Médico del Uruguay]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-03902022000201201</article-id>
<article-id pub-id-type="doi">10.29193/rmu.38.2.1</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Descripción de la disponibilidad y normas para el uso de las benzodiacepinas en algunos países de América Latina, 2022]]></article-title>
<article-title xml:lang="en"><![CDATA[Description of benzodiazepines availability and regulation in several countries of Latin America, 2022]]></article-title>
<article-title xml:lang="pt"><![CDATA[Descrição da disponibilidade e regulamentação para o uso de benzodiazepínicos em alguns países da América Latina, 2022]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Speranza Mourine]]></surname>
<given-names><![CDATA[Noelia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Viroga Espino]]></surname>
<given-names><![CDATA[Stephanie]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Naeko Uema]]></surname>
<given-names><![CDATA[Sonia Andrea]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pimentel Montero]]></surname>
<given-names><![CDATA[Fátima]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Calvo Barbado]]></surname>
<given-names><![CDATA[Dulce María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cañás]]></surname>
<given-names><![CDATA[Martín]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aldunate]]></surname>
<given-names><![CDATA[María Francisca]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramírez Camacho]]></surname>
<given-names><![CDATA[Mario Alberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Escalante Saavedra]]></surname>
<given-names><![CDATA[Pamela Alejandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,UDELAR Facultad de Medicina Hospital de Clínicas]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,UDELAR Facultad de Medicina Hospital de Clínicas]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Nacional de Córdoba Facultad de Ciencias Químicas Centro de Información de Medicamentos (CIME)]]></institution>
<addr-line><![CDATA[Córdoba ]]></addr-line>
<country>Argentina</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Universidad de Panamá Facultad de Farmacia Depto. de Farmacia Clínica]]></institution>
<addr-line><![CDATA[Ciudad de Panamá ]]></addr-line>
<country>Panamá</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Ministerio de Salud Pública Departamento de Farmacoepidemiología Centro de Información del Medicamento (CDF)]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Fundación FEMEBA (CIMEFF) Área de Farmacología ]]></institution>
<addr-line><![CDATA[La Plata ]]></addr-line>
<country>Argentina</country>
</aff>
<aff id="Af7">
<institution><![CDATA[,Instituto de Salud Pública de Chile Agencia Nacional de Medicamentos Subdepartamento Farmacovigilancia]]></institution>
<addr-line><![CDATA[Santiago ]]></addr-line>
<country>Chile</country>
</aff>
<aff id="Af8">
<institution><![CDATA[,Universidad Autónoma de Yucatán Facultad de Química Centro de Información de Medicamentos]]></institution>
<addr-line><![CDATA[Mérida ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af9">
<institution><![CDATA[,Conselho Federal de Farmácia (CEBRIM/CFF) Centro Brasileiro de Informação sobre Medicamentos ]]></institution>
<addr-line><![CDATA[Brasilia ]]></addr-line>
<country>Brasil</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<volume>38</volume>
<numero>2</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-03902022000201201&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-03902022000201201&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-03902022000201201&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  las benzodiacepinas constituyen un grupo farmacológico de amplia prescripción a nivel mundial desde su aparición en la década de 1960. El objetivo del presente estudio fue identificar la disponibilidad, las modalidades de prescripción y dispensación de benzodiacepinas en diferentes países de América Latina, según reglamentación vigente en cada país participante del estudio.  Materiales y métodos:  estudio observacional, descriptivo y transversal, realizado con los datos disponibles al año 2022 de todos los países miembros de la Red de Centros de Información de Medicamentos de LatinoAmérica y el Caribe (Red CIMLAC) que fueron parte del estudio. Se utilizaron las bases de datos de las agencias regulatorias, la reglamentación vigente y otros documentos necesarios para obtener la información sobre la dispensación y prescripción en cada país.  Resultados:  doce de los 20 países de la Red CIMLAC completaron el estudio. El total de benzodiacepinas disponible en cada país varió entre 6 y 12 (media: 9). De ellas, en promedio 5 estaban incluidas en listados de medicamentos esenciales nacionales. La mayoría de los países cuentan con combinaciones a dosis fijas con benzodiacepinas. En todos los países se realiza la prescripción por receta especial. Más de la mitad de los países cuentan con recomendaciones nacionales.  Conclusiones:  la amplia disponibilidad de benzodiacepinas comercializadas, la existencia de combinaciones a dosis fijas y la falta de recomendaciones nacionales pueden ser factores que contribuyan al uso irracional de este grupo terapéutico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Summary:  Introduction:  benzodiazepines constitute a widely prescribed group of drugs around the world, since they appeared in the sixties. This study aims to identify the availability, prescription modalities and dispensing of benzodiazepines in different countries around Latin America, as per the legal provisions in force in each of the countries participating in the study.  Method:  observational, descriptive, transversal study based on the information available in 2022 about all the member countries of the Network Medicines Information Centers of Latin America and the Caribbean (CIMLAC Network) that were part of the study. The databases of regulatory authorities were used and the legal provisions in force and relevant documents were consulted in order to obtain information on benzodiazepines dispensing and prescription in each country.  Results: twelve out of the 20 CIMLAC Network member countries completed the study. The total number of benzodiazepines available in the study ranged from 6 to 12 (mean was 9), and 5 of them on average were included in the national essential medications lists. Most countries have benzodiazepines fixed dose combinations and in all countries a special medical prescription is needed. More than half of the countries have national recommendations.  Conclusions: the wide availability of benzodiazepines in the market, the existence of fixed-dose combinations and the lack of national recommendations may constitute factors that contribute to the irrational use of this group of drugs.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução:  os benzodiazepínicos constituem um grupo farmacológico amplamente prescrito em todo o mundo desde seu surgimento na década de 1960. O objetivo deste estudo foi identificar a disponibilidade, prescrição e modalidades de dispensação de benzodiazepínicos em diferentes países da América Latina, de acordo com as regulamentações vigentes em cada país participante do estudo.  Materiais e métodos: estudo observacional, descritivo e transversal, realizado com os dados disponíveis até o ano de 2022 dos países membros da Rede de Centros de Informação sobre Medicamentos da América Latina e do Caribe (Red CIMLAC) que faziam parte do estudo. As bases de dados das agências reguladoras, normas vigentes e outros documentos necessários foram utilizados para obter informações sobre dispensação e prescrição em cada país.  Resultados: doze dos 20 países da Rede CIMLAC completaram o estudo. O número total de benzodiazepínicos disponíveis em cada país variou entre 6 e 12 (média: 9). Destes, uma média de 5 foram incluídos nas listas nacionais de medicamentos essenciais. A maioria dos países tem combinações de dose fixa com benzodiazepínicos. Em todos os países é necessário prescrição especial. Mais da metade dos países têm recomendações nacionais.  Conclusões: a ampla disponibilidade de benzodiazepínicos comercializados, a existência de combinações em doses fixas e a falta de recomendações nacionais podem ser fatores que contribuem para o uso irracional desse grupo terapêutico.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Benzodiazepinas]]></kwd>
<kwd lng="es"><![CDATA[Uso de medicamentos]]></kwd>
<kwd lng="es"><![CDATA[Servicios de información sobre medicamentos]]></kwd>
<kwd lng="es"><![CDATA[América Latina]]></kwd>
<kwd lng="en"><![CDATA[Benzodiazepines]]></kwd>
<kwd lng="en"><![CDATA[Medication use]]></kwd>
<kwd lng="en"><![CDATA[Drug information services]]></kwd>
<kwd lng="en"><![CDATA[Latin America]]></kwd>
<kwd lng="pt"><![CDATA[Benzodiazepinas]]></kwd>
<kwd lng="pt"><![CDATA[Uso de medicamentos]]></kwd>
<kwd lng="pt"><![CDATA[Serviços de informação sobre medicamentos]]></kwd>
<kwd lng="pt"><![CDATA[América Latina]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Charney]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Mihic]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hipnóticos y sedantes]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Goodman]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Gilman]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Las bases farmacológicas de la terapéutica]]></source>
<year>2007</year>
<edition>11</edition>
<page-range>401-27</page-range><publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[McGraw-Hill Interamericana]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jufe]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ansiolíticos e hipnóticos]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Jufe]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Psicofarmacología práctica]]></source>
<year>2001</year>
<page-range>119-69</page-range><publisher-loc><![CDATA[Buenos Aires ]]></publisher-loc>
<publisher-name><![CDATA[Polemos]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Catenaccio]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Sosa]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Danza]]></surname>
<given-names><![CDATA[Á]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Speranza]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Tamosiunas]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Promoviendo una prescripción racional de las benzodiacepinas]]></article-title>
<source><![CDATA[Bol farmacol]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sweetman]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
</person-group>
<collab>ed</collab>
<source><![CDATA[Martindale: The Complete Drug Reference]]></source>
<year>2011</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[The Royal Pharmaceutical Society of Great Britain]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<collab>Micromedex. POISINDEX(r) System</collab>
<source><![CDATA[Benzodiazepines]]></source>
<year></year>
<publisher-loc><![CDATA[Greenwood Village, CO ]]></publisher-loc>
<publisher-name><![CDATA[IBM]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<collab>Micromedex. CareNotes(r) System</collab>
<source><![CDATA[Benzodiazepines]]></source>
<year></year>
<publisher-loc><![CDATA[Greenwood Village, CO ]]></publisher-loc>
<publisher-name><![CDATA[IBM]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iñesta García]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudios de utilización de medicamentos]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Iñesta-García]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Sobre medicamentos y farmacoeconomía]]></source>
<year>2011</year>
<page-range>104-50</page-range><publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Escuela Nacional de Sanidad-Instituto de Salud Carlos III]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tamosiunas]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La prescripción de medicamentos en una sociedad medicalizada]]></article-title>
<source><![CDATA[Bol farmacol]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Utilización de medicamentos ansiolíticos e hipnóticos en España durante el período 2000-2012]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Furtado]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Psicofármacos: evolução do consumo em Portugal Continental (2000-2012)]]></article-title>
<source><![CDATA[]]></source>
<year></year>
<publisher-loc><![CDATA[Lisboa ]]></publisher-loc>
<publisher-name><![CDATA[Infarmed]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[António]]></surname>
<given-names><![CDATA[Â]]></given-names>
</name>
<name>
<surname><![CDATA[Remígio]]></surname>
<given-names><![CDATA[É]]></given-names>
</name>
</person-group>
<source><![CDATA[Evolução do consumo de benzodiazepinas em Portugal de 1995 a 2001]]></source>
<year></year>
<publisher-loc><![CDATA[Lisboa ]]></publisher-loc>
<publisher-name><![CDATA[Infarmed]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Speranza]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Pagano]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Artagaveytia]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Olmos]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Toledo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consumo de benzodiazepinas en la población uruguaya: un posible problema de salud pública]]></article-title>
<source><![CDATA[Rev Méd Urug]]></source>
<year>2015</year>
<volume>31</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>112-9</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quaglia Planas]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Paciaroni]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Elías]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Leiva]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consumo de benzodiazepinas en una comuna de la región metropolitana de Rosario, provincia de Santa Fe, Argentina]]></article-title>
<source><![CDATA[Aten Primaria]]></source>
<year>2009</year>
<volume>41</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>520-1</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marín]]></surname>
<given-names><![CDATA[GH]]></given-names>
</name>
<name>
<surname><![CDATA[Del Mauro]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Marin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Urtasun]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Marin]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Nucher]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consumo de benzodiazepinas y fármacos Z en una organización de la seguridad social nacional argentina: ¿uso racional o excesivo?]]></article-title>
<source><![CDATA[Salud colect]]></source>
<year>2021</year>
<volume>17</volume>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Urtasun]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Noble]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cañás]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bustin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Regueiro]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Triskier]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uso de benzodiazepinas y fármacos relacionados en el seguro social para adultos mayores de Argentina]]></article-title>
<source><![CDATA[Medicina (B.Aires)]]></source>
<year>2022</year>
<volume>82</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machado-Alba]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Alzate-Carvajal]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez-Canizales]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tendencias de consumo de medicamentos ansiolíticos e hipnóticos en una población colombiana, 2008-2013]]></article-title>
<source><![CDATA[Rev Colomb Psiquiat]]></source>
<year>2015</year>
<volume>44</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>93-9</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pimentel de Azevedo]]></surname>
<given-names><![CDATA[Â]]></given-names>
</name>
<name>
<surname><![CDATA[Antunes de Araújo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fernandes Ferreira]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consumo de ansiolíticos benzodiazepínicos uma correlação entre dados do SNGPC e indicadores sociodemográficos nas capitais brasileiras]]></article-title>
<source><![CDATA[Ciênc Saúde Colet]]></source>
<year>2016</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>83-90</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villagra]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Cabrera]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cordova]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consumo de benzodiazepinas en la población geriátrica atendida en el Hospital Clínico Regional de Concepción]]></article-title>
<source><![CDATA[Value Health]]></source>
<year>2015</year>
<volume>18</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>A832</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Masís Jiménez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudio de utilización de benzodiacepinas en el área de salud de cartago (CCSS), durante el período de febrero 2007 a enero 2008]]></article-title>
<source><![CDATA[Rev Méd Univ Costa Rica]]></source>
<year>2009</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>43-55</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Atencio]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Consumo cuantitativo de medicamentos controlados para uso médico, dispensados en la provincia de Panamá, durante el tercer trimestre del año 2011]]></source>
<year>2015</year>
<publisher-name><![CDATA[Universidad de Panamá. Facultad de Farmacia]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Domínguez]]></surname>
<given-names><![CDATA[RI]]></given-names>
</name>
</person-group>
<source><![CDATA[Consumo cuantitativo estimado de Medicamentos Controlados de Uso Médico, dispensados en la Provincia de Los Santos, durante los años 2011 a 2012]]></source>
<year>2015</year>
<publisher-name><![CDATA[Universidad de Panamá. Facultad de Farmacia]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jamoulle]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quaternary prevention, an answer of family doctors to overmedicalization]]></article-title>
<source><![CDATA[Int J Health Policy Manag]]></source>
<year>2015</year>
<volume>4</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>61-4</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gervás Camacho]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gavilán Moral]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevención cuaternaria: es posible (y deseable) una asistencia sanitaria menos dañina]]></article-title>
<collab>Jiménez de Gracia L</collab>
<source><![CDATA[AMF]]></source>
<year>2012</year>
<volume>8</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>312-7</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="">
<collab>Red de Centros de Información de Medicamentos de Latinoamerica y el Caribe</collab>
<source><![CDATA[Red CIMLAC]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="">
<collab>WHO Collaborating Centre for Drug Statistics Methodology</collab>
<source><![CDATA[Norwegian Institute of Public Health. ATC/DDD Index 2018]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[WHO model list of essential medicines-22nd list, 2021]]></source>
<year></year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
